Rationale, Development, and Validation of HdxSim, a Clinical Decision Support Tool for Model-Informed Precision Dosing of Hydroxyurea for Children with Sickle Cell Anemia. Clinical Pharmacology and Therapeutics. 2024; 116:670-677.
.Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial. The Lancet Haematology. 2024; 11:e425-e435.
.Successes and pitfalls in orphan drug development for sickle cell disease. Blood Advances. 2024; 8:2455-2465.
.Hydroxyurea reduces infections in children with sickle cell anemia in Uganda. Blood. 2024; 143:1425-1428.
.Reducing transfusion utilization for children with sickle cell anemia in sub-Saharan Africa with hydroxyurea: Analysis from the phase I/II REACH trial. American Journal of Hematology. 2024; 99:625-632.
.A Population Pharmacokinetic Analysis of L-Glutamine Exposure in Patients with Sickle Cell Disease: Evaluation of Dose and Food Effects. Clinical Pharmacokinetics. 2024; 63:357-365.
.2024; 1:100001.
. Angiopoietin-2 is associated with sickle cell complications, including stroke risk, and decreases with hydroxyurea therapy.The bold promise of gene therapy for sickle cell disease. British Journal of Haematology. 2024; 204:381-382.
.Screening for haemoglobin disorders: One size may not fit all. British Journal of Haematology. 2024; 204:26-28.
.Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens. Pharmacoeconomics Italian Research Articles. 2023; 41:1603-1615.
.2023; 142:797.
. Hydroxyurea Improves Intelligence Quotient Scores in Children with Sickle Cell Anemia and Elevated Transcranial Doppler Velocity. Blood.2023; 142:2530.
. A Novel, Rapid, and Accurate Quantitative Hydroxyurea Assay. Blood.2023; 142:1145.
. Effects of L-Glutamine on Biomarkers of Response in Sickle Cell Disease: A Pharmacokinetics-Pharmacodynamics Analysis. Blood.Codetection of Plasmodium falciparum in Children Hospitalized With Dengue Fever in the Dominican Republic. The Pediatric Infectious Disease Journal. 2023; 42:965-968.
.Simultaneous adjunctive treatment of malaria and its coevolved genetic disorder sickle cell anemia. Blood Advances. 2023; 7:5970-5981.
.Efficacy, safety, and pharmacokinetics of a new, ready-to-use, liquid hydroxyurea in children with sickle cell anemia. Blood Advances. 2023; 7:4319-4322.
.Defining global strategies to improve outcomes in sickle cell disease: a Lancet Haematology Commission. The Lancet Haematology. 2023; 10:e633-e686.
.Sustained and Boosted Antibody Responses in Breast Milk After Maternal SARS-CoV-2 Vaccination. Breastfeeding Medicine. 2023; 18:612-620.
.Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial. Blood Advances. 2023; 7:3023-3031.
.Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination. Vaccine. 2023; 41:4183-4189.
.Hydroxyurea pharmacokinetics and precision dosing in low-resource settings. Frontiers in Molecular Biosciences. 2023; 10:1130206.
.Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023; 43:419-429.
.Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. The Lancet Haematology. 2023; 10:e261-e271.
.Genome-wide association study of early ischaemic stroke risk in Brazilian individuals with sickle cell disease implicates ADAMTS2 and CDK18 and uncovers novel loci. British Journal of Haematology. 2023; 201:343-352.
.Hydroxyurea treatment is associated with lower malaria incidence in children with sickle cell anemia in sub-Saharan Africa. Blood. 2023; 141:1402-1410.
.Stroke Prevention with Hydroxyurea Enabled through Research and Education: A Phase 2 Primary Stroke Prevention Trial in Sub-Saharan Africa. Acta Haematologica. 2023; 146:95-105.
.Lack of hydroxyurea-associated mutagenesis in pediatric sickle cell disease patients. Environmental and Molecular Mutagenesis. 2023; 64:167-175.
.The Consortium on Newborn Screening in Africa for sickle cell disease: study rationale and methodology. Blood Advances. 2022; 6:6187-6197.
.Blood diseases in Africa: Redressing unjust disparities is an urgent unmet need. American Journal of Hematology. 2022; 97:1505-1506.
.2022; 140:8168-8169.
. Hydroxyurea Pharmacokinetics in Young Children with Sickle Cell Anemia: Results from the Therapeutic Response Evaluation and Adherence Trial (TREAT). Blood.2022; 140:8256-8257.
. Evaluation of Dosage and Food Effect on L-Glutamine Exposure for Sickle Cell Anemia: A Population Pharmacokinetic Analysis. Blood.2022; 6:1.
. O‐01: HYDROXYUREA REDUCES THE TRANSFUSION BURDEN IN CHILDREN WITH SICKLE CELL ANEMIA IN SUB‐SAHARAN AFRICA: THE REACH EXPERIENCE. HemaSphere.2022; 6:13.
. PI‐08: HIGH DISEASE BURDEN, MORBIDITY AND MORTALITY AMONG CHILDREN WITH SICKLE CELL ANAEMIA IN UGANDA. HemaSphere.2022; 6:7-8.
. O‐12: BUILDING LOCAL CAPACITY FOR HYDROXYUREA PHARMACOKINETICS AND PRECISION DOSING IN LOW‐RESOURCE SETTINGS. HemaSphere.New therapeutics for children with sickle cell disease: A time for celebration, caution, or both?. Pediatric Blood and Cancer. 2022; 69:e29805.
.US News & World Report and quality metrics: Inclusion of sickle cell disease is a matter of equity. Pediatric Blood and Cancer. 2022; 69:e29679.
.Case Report: β-thalassemia major on the East African coast. Wellcome Open Research. 2022; 7:188.
.Assessment of Plasmodium falciparum Artemisinin Resistance Independent of kelch13 Polymorphisms and with Escalating Malaria in Bangladesh. mBio. 2022; 13:e0344421.
.Reproductive equity: preserve the reserve. Blood. 2022; 139:963-965.
.Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria. Blood Advances. 2021; 5:4710-4720.
.Hydroxycarbamide treatment reduces transcranial Doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial Doppler velocity, and cerebral vasculopathy: the EXTEND trial. British Journal of Haematology. 2021; 195:612-620.
.Increased oxygen affinity: to have and to hold. Blood. 2021; 138:1094-1095.
.Microscope diagnosis of MYH9-related thrombocytopenia. Blood. 2021; 138:1000.
.Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response. Blood Cells, Molecules, and Diseases. 2021; 90:102576.
.Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease. British Journal of Haematology. 2021; 194:970-979.
.Operational analysis of the national sickle cell screening programme in the Republic of Uganda. African Journal of Laboratory Medicine. 2021; 10:1303.
.Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics-guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia. British Journal of Haematology. 2021; 194:617-625.
.Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020. PloS one. 2021; 16:e0254667.
.Newborn screening for sickle cell disease in sub-Saharan Africa: Is the glass half-full yet?. Pediatric Blood and Cancer. 2021; 68:e29137.
.Absence of hydroxyurea-induced mutational effects supports higher utilisation for the treatment of sickle cell anaemia. British Journal of Haematology. 2021; 194:252-266.
.Prospective Newborn Screening for Sickle Cell Disease and Other Inherited Blood Disorders in Central Malawi. International Journal of Public Health. 2021; 66:629338.
.Transfusion management of severe anaemia in African children: a consensus algorithm. British Journal of Haematology. 2021; 193:1247-1259.
.Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience. Pediatric Blood and Cancer. 2021; 68:e29008.
.Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial. JMIR Research Protocols. 2021; 10:e27650.
.Hydroxyurea Pharmacokinetics in Pediatric Patients After Total Pancreatectomy With Islet Autotransplantation. The Journal of Clinical Pharmacology. 2021; 61:547-554.
.Automated Oxygen Gradient Ektacytometry: A Novel Biomarker in Sickle Cell Anemia. Frontiers in Physiology. 2021; 12:636609.
.2021; 147:230-231.
. Bedside Expedited Testing for Anemia in Tanzania: the BETA Study. Pediatrics.There's safety in numbers. Blood. 2021; 137:729-731.
.Electrochemical Determination of Hydroxyurea in a Complex Biological Matrix Using MoS2-Modified Electrodes and Chemometrics. Biomedicines. 2021; 9.
.Trends in sickle cell trait and disease screening in the Republic of Uganda, 2014-2019. Tropical Medicine and International Health. 2021; 26:23-32.
.AnemoCheck-LRS: an optimized, color-based point-of-care test to identify severe anemia in limited-resource settings. BMC Medicine. 2020; 18:337.
.Surveillance for sickle cell disease, United Republic of Tanzania. Bulletin of the World Health Organization. 2020; 98:859-868.
.2020; 136:8-9.
. Genetic Variants That Influence Fetal Hemoglobin Expression from Hydroxyurea Treatment. Blood.2020; 136:16-17.
. Rapid and Automated Quantitation of Dense Red Blood Cells: A Robust Biomarker of Therapeutic Response to Early Initiation of Hydroxyurea in Young Children with Sickle Cell Anemia. Blood.2020; 136:33-34.
. Novel Genetic Loci That Influence Fetal Hemoglobin Expression in Children with Sickle Cell Anemia. Blood.Novel dose escalation to predict treatment with hydroxyurea (NDEPTH): A randomized controlled trial of a dose-prediction equation to determine maximum tolerated dose of hydroxyurea in pediatric sickle cell disease. American Journal of Hematology. 2020; 95:E242-E244.
.Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS). The Journal of Pediatrics. 2020; 222:236-239.
.Empowering newborn screening programs in African countries through establishment of an international collaborative effort. Journal of Community Genetics. 2020; 11:253-268.
.β-Thalassemia pathogenic variants in a cohort of children from the East African coast. Molecular Genetics and Genomic Medicine. 2020; 8:e1294.
.Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. The New England Journal of Medicine. 2020; 382:2524-2533.
.Effective use of hydroxyurea for sickle cell anemia in low-resource countries. Current Opinion in Hematology. 2020; 27:172-180.
.Perceived benefits and risks of participation in a clinical trial for Ugandan children with sickle cell anemia. Pediatric Blood and Cancer. 2020; 67:e27830.
.Springer Nature; Springer Nature; 2020.
. Sickle Cell Disease. Clinical Handbook of Psychological Consultation in Pediatric Medical Settings. :